Silvia Takanen

Dr. Silvia Takanen

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
STSilvia Takanen
Silvia Takanen
AGA. Gambirasio
A. Gambirasio
GGG. Gritti
G. Gritti
MKM. Källi
M. Källi
SAStefano Andreoli
Stefano Andreoli
LCL. F. Cazzaniga
L. F. Cazzaniga

22 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
STSilvia Takanen
Silvia Takanen
Marta  BotteroMarta Bottero
Marta Bottero
PNPaola Nisticò
Paola Nisticò
GSGiuseppe Sanguineti
Giuseppe Sanguineti
We investigated how hypofractionated radiotherapy (HFRT) and stereotactic body radiotherapy (SBRT) may impact immune cells in different type of tumors. A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The PubMed, Embase and Cochrane databases were searched. Overall, 11 studies met the inclusion criteria and were eligible for the present analysis. Both HFRT and SBRT have different impact on lymphocyte subpopulations, confirming their immunomodulatory effect which may have a crucial role in future combined treatment with new emergent therapies such as immunotherapy. Further studies are needed to shed more light on this emerging topic to ultimately improve patient care, treatment and clinical benefits for cancer patients.

11 October 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
STSilvia Takanen
Silvia Takanen
CBCaterina Bangrazi
Caterina Bangrazi
VGVanessa Graziano
Vanessa Graziano
APAlessandro Parisi
Alessandro Parisi
BRBlerina Resuli
Blerina Resuli
VTVincenzo Tombolini
Vincenzo Tombolini
Currently the most important prognostic factor in lung cancer is the stage. In the current lung TNM classification system, N category is defined exclusively by anatomic nodal location though, in other type of tumours, number of lymph nodes is confirmed to be a fundamental prognostic factor. Therefore we evaluated the number of mediastinal lymph nodes as a prognostic factor in locally advanced NSCLC after multimodality treatment, observing a significant effect of the number of lymph nodes in terms of OS (p<0.01) and DFS (p<0.001): patients with a low number of positive mediastinal nodes have a better prognosis.

5 September 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
STSilvia Takanen
Silvia Takanen
AIAnna Ianiro
Anna Ianiro
PPPaola Pinnarò
Paola Pinnarò
EIErminia Infusino
Erminia Infusino
LMLaura Marucci
Laura Marucci
GIGiuseppe Iaccarino
Giuseppe Iaccarino
Background: In high-risk breast cancer patients with skin infiltration, the administration of a uniform dose to superficial tissues is fundamental in order to reduce local skin relapse. A personalized bolus may prevent the potential inadequate dose distribution of a standard bolus due to air gaps between the bolus and the skin. In this pilot study, we introduced into clinical practice the use of a personalized 3D-printed bolus filled with ultrasound transmission gel. Methods: Seven patients undergoing radiotherapy after mastectomy were selected. A 3D-printed bolus dosimetric assessment was performed with MOSFET dosimeters on an anthropomorphic phantom and, subsequently, on three selected cases with increasing bolus shape irregularity. Acute/late toxicity and local control were assessed. Results: Overall, for the clinical cases, the percentage median difference between the measured and calculated doses was −2.7% (−7.0–4.9%). The median follow-up was 21 months. After two years, one patient showed G2 pain, one patient manifested G1 telangiectasia, one patient showed G1 hyperpigmentation, and two patients had no relevant toxicity. Conclusions: A personalized 3D-printed bolus filled with ultrasound gel may easily reproduce the standard bolus’ consistency and provide accurate coverage of the target area with tolerable acute/late toxicity grades. This is a pilot study, and further investigations are needed.

13 October 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
STSilvia Takanen
Silvia Takanen
PPPaola Pinnarò
Paola Pinnarò
IFIlaria Farina
Ilaria Farina
FSFrancesca Sperati
Francesca Sperati
CBClaudio Botti
Claudio Botti
GSGiuseppe Sanguineti
Giuseppe Sanguineti
In selected low-risk breast cancer patients, accelerated partial breast irradiation (APBI) may represent an alternative option to the whole breast irradiation to reduce the volume of irradiated breast and total treatment duration. In the last few years, preliminary data from clinical trials showed that stereotactic partial breast radiotherapy may have the advantage to be less invasive compared to other APBI techniques, with preliminary good results in terms of local toxicity and cosmesis: the use of magnetic resonance, fiducial markers in the tumor bed, and new breast devices support both a precise definition of the target and radiation planning.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021257856, identifier CRD42021257856.

1 September 2013 in Tumori Journal
Verified
Journal Article
Closed access
STSilvia Takanen
Silvia Takanen
CBCaterina Bangrazi
Caterina Bangrazi
RCRossella Caiazzo
Rossella Caiazzo
NRNicola Raffetto
Nicola Raffetto
VTVincenzo Tombolini
Vincenzo Tombolini
Extracranial metastases from glioblastoma multiforme (GBM) are a very rare event, even if an increasing incidence has been documented. We report the case of a young woman with primary GBM who developed bone metastases without local brain relapse. Because of persistent headache and visual disturbances, in March 2011 the patient underwent magnetic resonance imaging (MRI) evidencing a temporoparietal mass, which was surgically resected. Histology revealed GBM. She was given concomitant chemoradiotherapy according to the Stupp regimen. After a 4-week break, the patient received 6 cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days. In December 2011 she complained of progressive low back pain, and MRI showed multiple bone metastases from primary GBM, confirmed by histology. Cases of metastatic GBM in concurrence with a primary brain tumor or local relapse are more common in the literature; only a few cases have been reported where extracranial metastases from GBM occurred without any relapse in the brain. Here we report our experience.